RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$126.6B
P/E ratio
32x
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2010		Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Net income-104-2227504243486368961,1992,4442,1163,5138,0754,3383,954
Depreciation and amortization20-37415375105145148210236286341421
Stock-based compensation expense-5694198307459560507427464432602725885
Losses (gains) on marketable and other securities, net-------------37-266
Other non-cash items, net--10-34-24-30-34-45-64-1229135-569-3680
Deferred income taxes----67122360-319140131-76147746838
Research and Development in Process------------195-
(Increase) decrease in accounts receivable2821590199624911443632694731,3561,927-708339
Increase in inventories---4861112150314388336529494697272
Increase in prepaid expenses and other assets-3653533879-2411356130-115241149120
Increase (decrease) in deferred revenue---------194294148-1203238
Increase (Decrease) in Accounts Payable and Accrued Liabilities85011137162304254-23210445119866-138599
Total adjustments20180-825159395695578109-249314-895-994677640
Net cash provided by operating activities96-142-755847431,3311,4731,3072,1952,4302,6187,0815,0154,594
Purchases of marketable and other securities6052404705775645578091,2771,8463,2023,2417,0487,48811,646
Sales or maturities of marketable and other securities2774264393784763272745457761,6043,7852,2155,5519,442
Capital expenditures1005749156333678512273383430615552590719
Payments for Libtayo intangible asset------------1,027208
Asset acquisition, net of cash acquired------------230-
Acquisitions, net of cash acquired-------------55
Net cash used in investing activities-434128-81-355-421-908-1,047-1,005-1,463-2,028-71-5,385-3,785-3,185
Proceeds from issuance of Common Stock1971964571262061272401152122,5751,6721,5201,146
Payments in connection with Common Stock tendered for employee tax obligations--1631952681611433021871886811,033446701
Repurchases of Common Stock--------42765,8471,6452,0832,235
Proceeds from issuance of long-term debt----------1,982---
Net cash used in financing activities243384-9877-209-263-700-24-77-252-1,970-1,006-1,009-1,790
Proceeds from Short-Term Debt----------1,500---
Repayment of bridge loan facility----------1,500---
Net cash used in financing activities243384-9877-209-263-700-24-77-252-1,970-1,006-1,009-1,790
Net (decrease) increase in cash, cash equivalents, and restricted cash---------150577691221-382
Effect of exchange rate changes on cash, cash equivalents, and restricted cash--------------0
Net (decrease) increase in cash, cash equivalents, and restricted cash---------150577691221-382
Cash paid for interest (net of amounts capitalized)-1522242111519222523565473
Income Taxes Paid, Net----602764817552063421881,2181,502870
Cash paid for interest (net of amounts capitalized)-1522242111519222523565473
Income Taxes Paid, Net----602764817552063421881,2181,502870